GSK plc (NYSE:GSK) Shares Bought by Bogart Wealth LLC

Bogart Wealth LLC boosted its stake in shares of GSK plc (NYSE:GSK) by 98.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 1,333 shares of the pharmaceutical company’s stock after purchasing an additional 662 shares during the period. Bogart Wealth LLC’s holdings in GSK were worth $54,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of GSK. Eastern Bank acquired a new stake in GSK during the third quarter worth about $26,000. Register Financial Advisors LLC purchased a new position in shares of GSK during the 1st quarter valued at approximately $31,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK in the 2nd quarter valued at $37,000. PrairieView Partners LLC purchased a new stake in GSK during the second quarter worth $47,000. Finally, Triad Wealth Partners LLC acquired a new stake in GSK during the second quarter valued at $49,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on GSK shares. UBS Group downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group boosted their price objective on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Barclays upgraded GSK to a “hold” rating in a research report on Tuesday, August 27th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $50.00.

GSK Stock Performance

NYSE GSK opened at $37.75 on Friday. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92. The company has a market cap of $78.24 billion, a PE ratio of 13.68, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The stock’s 50 day simple moving average is $41.27 and its 200-day simple moving average is $41.19.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Shareholders of record on Friday, August 16th were issued a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a yield of 4.07%. GSK’s dividend payout ratio is presently 55.80%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.